Am Fam Physician. 2001 Mar 1;63(5):848.
to the editor: I was pleased to read the article1 on management of nonmalignant pain. The undertreatment of pain is a widespread issue in the United States, and helping to educate practicing family physicians in the most current pain management techniques is an important, even critical, goal.
I was disappointed, however, by the relative lack of information in the article on the two newest classes of oral analgesics: (1) tramadol (Ultram) and (2) cyclooxygenase-2 (COX-2) inhibitors, which represent a new type of non-steroidal anti-inflammatory drug (NSAID).
Tramadol has been available in the United States for five years. It is effective not only for an acute episode of neuropathic pain (as suggested in the article), but also for chronic neuropathic pain syndrome, fibromyalgia, osteoarthritis pain2 and chronic low back pain.3 Tramadol may be most notable for what it is not—tramadol is not an NSAID, nor is it a typical opioid. Tramadol has a dual mechanism of action: it acts centrally at μ-opioid receptors and acts spinally, inhibiting the reuptake of monoamines (serotonin and nor-epinephrine). This may explain why tramadol and antidepressants are effective for some analgesic-resistant pain states.4
COX-2 inhibitors (rofecoxib [Vioxx] and celecoxib [Celebrex]) are used for a variety of indications: acute pain, dysmenorrhea and osteoarthritis. Further research is needed on the use of these drugs in the treatment of other painful states, but it is reasonable to assume, based on the available evidence, that COX-2 inhibitors are generally as effective as nonselective NSAIDs. Therefore, in cases of acute low back pain or chronic nonmalignant pain, COX-2 inhibitors should be especially useful for patients with inflammation and who are at high risk for gastrointestinal bleeding. Patients with such risk factors include those receiving treatment with “dual” NSAIDs, those receiving concomitant gluco-corticoid treatment, those with a history of gastroduodenal ulcers or bleeding and those receiving anticoagulation therapy.5,6
The use of COX-2 inhibitors may be appropriate in chronic and acute pain states; however, they may still be associated with non-gastrointestinal adverse events (e.g., renal, hepatic, cardiovascular).5,6
It is critically important that family physicians continue to be familiar with all aspects of pain management. I commend your efforts to call attention to the importance of this subject in primary care.
Dr. Barkin is affiliated with the Speaker's Bureau for the following organizations: Abbott Laboratories, Astra USA, Athena Neurosciences Inc., Baxter Healthcare, Bristol-Myers Squibb, Eli Lilly and Co., Glaxo Wellcome Inc., Janssen Pharmaceuticals, Knoll Pharmaceutical Co., Merck & Co., Novartis Pharmaceutical Corp., Ortho-McNeil Pharmaceutical Corp., Organon, Inc., Parke-Davis, Purdue Frederick, Smithkline Beecham and Wyeth Laboratories.
1. Marcus DA. Treatment of nonmalignant chronic pain. Am Fam Physician. 2000;61:1331–8.
2. Schnitzer TJ, Kamin M, Olson WH. Tramadol allows reduction of naproxen dose among patients with naproxen-responsive osteoarthritis pain: a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 1999;42:1370–7.
3. Schnitzer TJ, Gray WL, Paster RZ, Kamin M. Efficacy of tramadol in treatment of chronic low back pain. J Rheumatol. 2000;27:772–8.
4. Barkin RL, Fawcett J. The management challenges of chronic pain: the role of antidepressants. Amer J Ther. 2000;7:31–47.
5. Venkat K, Brown MD, Barkin RL. Nonsteroidal anti-inflammatory drugs and gastroduodenal injury. Am J Ther. 1998;5:263–72.
6. Barkin RL, Soble KS. Caution recommended for prescribing and administering COX 1/COX 2 and COX 2 specific NSAIDs. P&T. 2000;4:196–201.
editor's note: A copy of this letter was sent to the author of “Treatment of Nonmalignant Chronic Pain,” who declined to reply.
Send letters to Kenneth W. Lin, MD, MPH, Associate Deputy Editor for AFP Online, e-mail: email@example.com, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680.
Please include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.
Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the American Academy of Family Physicians permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.
Copyright © 2001 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions